Earth Science Tech (ETST) 8-K/A Completion of Acquisition or Disposition of Assets

Exhibit 99.4

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Defined terms included below have the same meaning as terms defined and included elsewhere in this Current Report on Form 8-K (this “Form 8-K”) and, if not defined in this Form 8-K, the Original Report.

Introduction

The unaudited pro forma condensed combined balance sheet as of September 30, 2022, and year ended March 31, 2022, gives pro forma effect to the Business Combination as if it had been consummated as of that date. The unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2022, and year ended March 31, 2022, give pro forma effect to the Business Combination as if it had occurred as of April 1, 2021. This information should be read together with Earth Science Tech, Inc. (“ETST”) audited financial statements for the year ended March 31, 2022 and related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations of ETST for the year ended March 31, 2022 included incorporated by reference into this Form 8-K, and PEAK S CURATIVE, LLC’S (“PEAKS”) audited financial statements for the year ended September 30, 2022 and related notes and RXCOMPOUNDSTORE.COM, LLC (“RXCOMPOUND”) , included in this Form 8-K.

The unaudited pro forma condensed combined balance sheet as of September 30, 2022, has been prepared using the following:

● ETST’s audited historical balance sheet as of March 31, 2022, incorporated by reference into this Form 8-K.

● PEAK’s audited historical balance sheet as of September 30, 2022, included in this Form 8-K.

● RXCOMPOUND’s audited historical balance sheet as of September 30, 2022, included in this Form 8-K.

The unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2022, and year ended March 31, 2022, has been prepared using the following:

● ETST’s audited historical consolidated statement of operations for the year ended March 31, 2022, incorporated by reference into this Form 8-K.; and

● PEAK’s audited historical statement of operations for the year ended September 30, 2022 (1^st year of operations), included in this Form 8-K.

● RXCOMPOUND’s audited historical statement of operations for the period ended September 30, 2022, and March 31, 2022, included in this Form 8-K.

Description of the Transactions

On November 8, 2022, Earth Science Tech, Inc. (“the Company”) acquired Peaks Curative, LLC. (“LLC”) a Florida limited liability company (“PEAKS”), and RxCompoundStore.com, LLC. (“RXCOMPOUND”). for 53,700,000 restricted shares of the Company’s common stock, and the assumption of certain indebtedness of PEAKS and RXCOMPOUND. PEAKS had one managing member, Mario G. Tabraue, who formed the LLC and established the company’s brand and website, and who was appointed to the Company as its President and a member of the board of directors on November 3, 2021, as part of a definitive agreement to be acquired by the Company. Pursuant to the definitive agreement the Company set terms for the transaction that was subsequently consumated on November 8, 2022, for 53,700,000 of the Company’s restricted common stock along with the PEAKS sister company, RxCompoundStore.com, LLC. (“RXCOMPOUND”). The shares issued consummated a merger, presently having the Company’s owned 100% by ETST

Accounting for the Merger

The Merger will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, PEAKS AND RXCOMPOUND, who are the legal acquirers, will be treated as the “acquired” companies for financial reporting purposes and ETST will be treated as the accounting acquirer. This determination was primarily based on PEAKS and RXCOMPOUND having a majority of the voting power of the post-combination company, PEAKS and RXCOMPOUND’s senior management comprising substantially all of the senior management of the post-combination company, the relative size of PEAKS and RXCOMPOUND combined compared to ETST, and PEAKS and RXCOMPOUND operations comprising the ongoing operations of the post-combination company. Accordingly, for accounting purposes, the Merger will be treated as the equivalent of a capital transaction in which ETST is issuing stock for the net assets of PEAKS and RXCOMPOUND. The net assets of PEAKS and RXCOMPOUND will be stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Merger will be those of ETST.

Basis of Pro Forma Presentation

The historical financial information has been adjusted to give pro forma effect to events that are related and/or directly attributable to the Business Combination. The adjustments presented on the unaudited pro forma combined financial statements have been identified and presented to provide relevant information necessary for an accurate understanding of the post-combination company upon consummation of the Business Combination. The unaudited pro forma condensed combined financial information is for illustrative purposes only. The financial results may have been different had the companies always been combined. You should not rely on the unaudited pro forma combined financial information as being indicative of the historical financial position and results that would have been achieved had the companies always been combined or the future financial position and results that the post-combination company will experience. ETST, PEAKS and RXCOMPOUND did not have any historical relationship prior to the Purchase Agreement dated November 3, 2021 later amended and consummated on November 8, 2022.

EARTH SCIENCES TECH , INC. & SUBSIDIARIES

PRO FORMA CONDENSED COMBINED BALANCE SHEETS (Unaudited)

	SEPTEMBER 30,2022																MARCH 31. 2022
											Merger			Pro Forma													Merger			Pro Forma
	EARTH SCIENCES TECH INC.			PEAKS CURATIVE LLC			RX COMPOUNDSTORE.COM LLC				Adjustments			Combined			EARTH SCIENCES TECH INC.			PEAKS CURATIVE LLC			RX COMPOUNDSTORE.COM LLC				Adjustments			Combined
	(Public Co.)			(Private Co.)			(Private Co.)										(Public Co.)			(Private Co.)			(Private Co.)
	Accounting			Accounting			Accounting										Accounting			Accounting			Accounting
	Acquiror			Acquiree			Acquiree										Acquiror			Acquiree			Acquiree
ASSETS
CURRENT ASSETS:
Cash	$	1,205		$	545			5,663							7,413		$	26,942		$	545			4,829							32,316
Inventory		-						10,259							10,259			-						10259							10,259
Other current assets		-						224,873							224,873			-						116405							116,405
TOTAL CURRENT ASSETS		1,205			545			240,795							242,545			26,942			545			131493							158,980
OTHER ASSETS
Due from RxCompound		303,057			-0			-0		bb		(303,057	)		-			25,000			-			-		bb		(25,000	)		25,000
Prepaid acquisition costs		51,500			-0			-0							51,500			25,000			-			-							25,000
TOTAL OTHER ASSETS		354,557			-0			-0							51,500			50,000			-0			-0							50,000
PROPERTY AND EQUIPMENT, net		-			-			-							-			-			-			-							-
INTANGIBLE ASSET, NET		-0			17,806										17,806			-0			19,209										19,209
Total assets	$	355,762		$	18,351			240,795		bb		(303,057	)	$	311,851		$	76,942		$	19,754			131493		bb		(25,000	)		228,189
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
CURRENT LIABILITIES
Accounts payable and accrued expenses	$	357,397			-			25532							382,929		$	611,784			-			17,806							629,590
Current portion of Notes payable		820,000			-			-0							820,000			406,838			-			-							406,838
Government Loans		111,752			-			-0							111,752			138,550			-			-							138,550
Loan payable		50,000			-			-0				-0			50,000			50,000			-			-							50,000
Notes Payable - Related Parties		88,505			-			-0							88,505			87,402			-			-							87,402
Due to ETST		-			-			286,000		bb		(286,000	)		-			-			-			30,000		bb		(30,000	)		-
Due to RX		110,363			-					bb		(110,363	)		-			1,895			-					bb		(1,895	)		-
Other current liabilities		845,318			-			-0							845,318			585,886			-0			-							585,886
TOTAL CURRENT LIABILITIES		2,383,335			-0			311,532		bb		(396,363	)		2,298,504			1,882,355			-0			47,806		bb		(31,895	)		1,898,266
NON-CURRENT LIABILITIES
Notes payable		-			-			108,700							108,700			-			-			108,700							108,700
TOTAL NON-CURRENT LIABILITIES		-			-			108,700							108,700			-0			-0			108,700							108,700
TOTAL LIABILITIES		2,383,335			-0			420,232							2,803,567			1,882,355			-			156,506							2,038,861
STOCKHOLDERS’/MEMBERS’ EQUITY (DEFICIT):
Preferred stock		1,000			-0			-0							1,000			-						-							-
Common stock		59,053			-0			-0		aa		53,700			59053			53,853						-		aa		53,700			53,853
Common Units					30,217					aa		(44,252	)		(30,217	)					21,867					aa		(36,401	)		21,867
Opening balance equity								73,190							73,190									73,190							73,190
Shareholders distribution								(6,180	)						(6,180	)								(5,680	)						(5,680	)
Additional paid-in capital		28,264,452			0			-0		aa		(241,378	)		28,264,452			28,264,452			-0					aa		(41,499	)		28,264,452
Accumulated earnings (deficit)		(30,352,078	)		(11,866	)		(24644	)	aa		231,930			(30,610,391	)		(30,123,718	)		(2,113	)		(92,523	)	aa		74,201			(30,219,354	)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)		(2,027,573	)		18,351			(179,437	)						(2,188,659	)		(1,805,413	)		19,754			(25,013	)						(1,810,672	)
Total liabilities and Equity	$	355,762		$	18,351		$	240795				(303,057	)		311,851		$	76,942		$	19,754			131,493				25,000			228,189

See accompanying notes to the Unaudited Pro Forma Condensed Combined Financial Information

EARTH SCIENCES TECH, INC. & SUBSIDIARIES

PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS (Unaudited)

	SIX MONTHS ENDED SEPTEMBER 30,2022																YEAR ENDED MARCH 31, 2022
	EARTH SCIENCES TECH INC.			PEAKS CURATIVE LLC			RX COMPOUNDSTORE.COM										EARTH SCIENCES TECH INC.			PEAKS CURATIVE LLC			RX COMPOUNDSTORE.COM
	(Public Co.)			(Private Co.)			(Private Co.)										(Public Co.)			(Private Co.)			(Private Co.)
	Accounting			Accounting			Accounting				Merger			Pro Forma			Accounting			Accounting			Accounting				Merger			Pro Forma
	Acquiror			Acquiree			Acquiree				Adjustments			Combined			Acquiror			Acquiree			Acquiree				Adjustments			Combined
REVENUES
Net Sales		-		$	1,134			101,378							102,512		$	14,123			-			255,176							269,299
TOTAL REVENUES
COST OF REVENUES		-			398			50,128							50,526			22,639			-			38,720							61,359
GROSS PROFIT		-			736			51,250							51,986			(8,516	)		-			216,456							207,940
OPERATING EXPENSES
Sales and Marketing					544			444-							988			3,655			381			-							4,036
General and administrative		246,160			12,058			204,728							462,946			207,035			1,173			296,582							504,790
Litigation expense		522,925			-			-							522,925			7,500			-			-							7,500
Total expenses		769,085			12,602			205,172							986,859			218,190			1,554			(80,126	)						516,326
INCOME (LOSS) FROM OPERATIONS		(769,085	)		(11,866	)		(153,922	)						(934,873	)		(226,706	)		(1,554	)		(80,126	)						(308,386	)
OTHER INCOME (EXPENSE)
Interest expense		(17,300	)		-			(1	)						(17,301	)		(50,043	)		-										(50,043	)
Other income (expense)		558,025			-										585,025			3,450,009			-										3,450,009
TOTAL OTHER INCOME (EXPENSE)		540,725			-			(1	)						540,724			3,399,966			-										3,399,966
NET INCOME (LOSS)	$	(228,360	)	$	(11,866	)		(153,923	)						(394,149	)	$	3,173,260		$	(1,554	)		(80,126	)						3,091,580
Common stock/units outstanding		59,051,966			1,000			-		aa		(1,000	)		59,051,966			53,851,966			1,000			-		aa		(1,000	)		53,851,966
Common stock issued in merger		-								aa		53,700,000			53,700,000			-								aa		53,700,000			53,700,000
Total common stock /units outstanding		59,051,966			1,000			-							112,751,966			53,851,966			1,000			-							107,551,966
NET LOSS PER SHARE	$	(0.0039	)											$	(0.0038	)		0.0589												$	0.0287

See accompanying notes to the Unaudited Pro Forma Condensed Combined Financial Information

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

1. Unaudited Pro Forma Condensed Combined Balance Sheet Adjustments

aa	Reflects the recapitalization of PEAKS and RXCOMPOUND through (i) the exchange of 100% of the common units of PEAKS and RXCOMPOUND for 53,700,000 shares of common stock of ETST public stock on a 1:1 exchange basis, (ii) the elimination of the historical retained earnings of PEAKS and RXCOMPOUND.
bb	Reflects the settlement of the outstanding loans receivable/loans payable between ETST, PEAKS and RXCOMPOUND upon the closing of the Merger.